NTRK1 and neoplasm: Recent clinical trials, namely ALKA-372-001, STARTRK-1, and STARTRK-2, evaluated the anti-tumor efficacy and safety of entrectinib, another TRK inhibitor, in patients with solid tumors displaying TRK gene fusions.